The Prognostic Significance of Postoperative Adjuvant Chemotherapy in the Population Aged 75 Years and Older with Stage II–III Colorectal Cancer: A Retrospective Multi-Center Cohort Study

References

• Siegel RL, Miller KD, Sauer AG, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145–164. doi:10.3322/caac.21601
   PubMed Web of Science ®Google Scholar
• Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Center. 2022;2(1):1–9. doi:10.1016/j.jncc.2022.02.002
   Google Scholar
• Dienstmann R, Mason MJ, Sinicrope FA, et al. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol. 2017;28(5):1023–1031. doi:10.1093/annonc/mdx052
   PubMed Web of Science ®Google Scholar
• Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2017;23(1):1–34. doi:10.1007/s10147-017-1101-6
   PubMed Web of Science ®Google Scholar
• Benson AB, Venook AP, Cederquist L, et al. Colon cancer, Version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Comprehen Cancer Netw. 2017;15(3):370. doi:10.6004/jnccn.2017.0036
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–1422. doi:10.1093/annonc/mdw235
   PubMed Web of Science ®Google Scholar
• Christophe T, Thierry A, Franck B, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol. 2012;30(27):3353–3360. doi:10.1200/JCO.2012.42.5645
   PubMed Web of Science ®Google Scholar
• Tan K-Y, Konishi F, Suzuki K. The evidence for adjuvant treatment of elderly patients (age > or = 70) with stage III colon cancer is inconclusive. Surg Today. 2010;40(4):385–387. doi:10.1007/s00595-009-4047-0
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345(15):1091–1097. doi:10.1056/NEJMoa010957
   PubMed Web of Science ®Google Scholar
• McCleary NJ, Meyerhardt JA, Green E, Yothers G, de Gramont A. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol. 2013;31(20):2600–2606. doi:10.1200/JCO.2013.49.6638
   PubMed Web of Science ®Google Scholar
• Yothers G, O’Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29(28):3768–3774. doi:10.1200/JCO.2011.36.4539
   PubMed Web of Science ®Google Scholar
• Andre T. Oxialiplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–2351 doi:10.1056/NEJMOA032709
   PubMed Web of Science ®Google Scholar
• Philip KJ, Samuel WH, Michael J O, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25(16):2198–2204. doi:10.1200/JCO.2006.08.2974
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495–1499. doi:10.1016/j.ijsu.2014.07.013
   PubMed Web of Science ®Google Scholar
• Benson AB, Venook AP, Al-Hawary MM, Cederquist L, et al. NCCN Guidelines Insights: Colon Cancer, Version 2.2018. J Natl Compr Canc Netw. 2018;16(4):359–369. doi:10.6004/jnccn.2018.0021
   PubMed Web of Science ®Google Scholar
• Benson AB, Venook AP, Al-Hawary MM, et al. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16(7):874–901. doi:10.6004/jnccn.2018.0061
   PubMed Web of Science ®Google Scholar
• Renehan AG, Malcomson L, Emsley R, Gollins S, Maw A. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol. 2015;17(2):174–183. doi:10.1016/S1470-2045(15)00467-2
   PubMed Web of Science ®Google Scholar
• Xiao L, Zhang C, Sun Z, Yang F, Xiao R. Propensity-matched analysis of adjuvant chemotherapy for completely resected Stage IB non-small-cell lung cancer patients. Lung Cancer. 2019;133:75–82. doi:10.1016/j.lungcan.2019.04.024
   PubMed Web of Science ®Google Scholar
• Schulz KF, Altman DG, Moher D. CONSORT Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials. PLoS Med. 2010;7(3):e1000251.
   PubMed Web of Science ®Google Scholar
• Tominaga T, Nonaka T, Oyama S, Shiraishi T, Takeshita H. Effect of oxaliplatin in elderly colon cancer patients with pathological T4 and/or N2 disease: a multicenter, propensity score-matched analysis. Int J Colorectal Dis. 2022;37(5):1181–1188. doi:10.1007/s00384-022-04159-x
   PubMed Web of Science ®Google Scholar
• André T, de Gramont A, Vernerey D. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol. 2015;33(35):4176–4187. doi:10.1200/JCO.2015.63.4238
   PubMed Web of Science ®Google Scholar
• Hurria A, Lichtman SM. Clinical pharmacology of cancer therapies in older adults. Br J Cancer. 2008;98(3):517–522. doi:10.1038/sj.bjc.6604201
   PubMed Web of Science ®Google Scholar
• Tominaga T, Nonaka T, Sumida Y, Hidaka S, Sawai T, Nagayasu T. Effectiveness of adjuvant chemotherapy for elderly patients with lymph node-positive colorectal cancer. World J Surg Oncol. 2016;14(1):197. doi:10.1186/s12957-016-0959-5
   PubMedGoogle Scholar
• Sanoff HK, Carpenter WR, Stürmer T, Goldberg RM, Martin CF. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagn osed after age 75 years. J Clin Oncol. 2012;30(21):2624–2634. doi:10.1200/JCO.2011.41.1140
   PubMed Web of Science ®Google Scholar
• André T, Meyerhardt J, Iveson T, Sobrero A, Yoshino T. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, Phase 3 trials. Lancet Oncol. 2020;21(12):1620–1629. doi:10.1016/S1470-2045(20)30527-1
   PubMed Web of Science ®Google Scholar